MaxCyte launches CHANGE-seq-BE™ and ONE-seq-BE™ to strengthen off-target assessment for genome editing therapies
Globe Newswire•19/08/2026•08:05 ET
0
Whiz Insights
Get started
Create a free account to read the full story.
Create a free account to read the full story.